Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications (Q30817266)

26 June 2017

1 reference

title

Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications (English)

1 reference

26 June 2017

Riveline JP

1

1 reference

26 June 2017

Danchin N

2

1 reference

26 June 2017

Ledru F

3

1 reference

26 June 2017

Varroud-Vial M

4

1 reference

26 June 2017

Charpentier G

5

1 reference

26 June 2017

1 June 2003

1 reference

26 June 2017

Diabetes and Metabolism

1 reference

26 June 2017

29

1 reference

26 June 2017

3

1 reference

26 June 2017

207-222

1 reference

A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP)

26 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Myocardial infarction in the diabetic patient

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Coronary care for myocardial infarction in diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Determinants of Hospital Admission and Case Fatality in Diabetic Patients With Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Vascular complications and long-term administration of oral hypoglycemic agents in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Randomized controlled trials remain fundamental to clinical decision making in Type II diabetes mellitus: a comment to the debate on randomized controlled trials (For debate) [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Diabetes and coronary artery disease: time to stop taking the tablets?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Comparative aspects of the function and mechanism of SUR1 and MDR1 proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

An explanation for the reported observation that ATP dependent potassium channel openers mimic preconditioning

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Influence of ATP-sensitive potassium channel modulators on ischemia-induced fibrillation in isolated rat hearts

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of glibenclamide on ventricular arrhythmias and cardiac function in ischaemia and reperfusion in isolated rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effect of blockade of the ATP-sensitive potassium channel on metabolic coronary vasodilation in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Blockade of ATP-sensitive potassium channels increases infarct size but does not prevent preconditioning in rabbit hearts.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Role of ATP-sensitive K+ channel on ECG ST segment elevation during a bout of myocardial ischemia. A study on epicardial mapping in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Cardioprotective actions of potassium channel openers

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effect of nicorandil on post-ischaemic contractile dysfunction in the heart: roles of its ATP-sensitive K+ channel opening property and nitrate property

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of intracoronary cromakalim on postischaemic contractile function and action potential duration

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Glibenclamide does not abolish the protective effect of preconditioning on stunning in the isolated perfused rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

ATP gated potassium channels in acute myocardial hibernation and reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

The protection by ischemic preconditioning against myocardial ischemia- and reperfusion-induced arrhythmias is not mediated by ATP-sensitive potassium channels in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Ketamine-xylazine anaesthesia permits a KATP channel antagonist to attenuate preconditioning in rabbit myocardium.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Actions of pinacidil at a reduced potassium concentration: a direct cardiac effect possibly involving the ATP-dependent potassium channel

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Reduction of ischemic K+ loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Glibenclamide does not prevent action potential shortening induced by ischemia in anesthetized rabbits but reduces ischemia-induced arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Concerning the effect of the K+ channel blocking agent glibenclamide on ischaemic and reperfusion arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Are ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Structural basis for the interference between nicorandil and sulfonylurea action

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Cardiovascular effects of conventional sulfonylureas and glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Oral hypoglycemic sulfonylurea glimepiride preserves the myoprotective effects of ischemic preconditioning

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of tolbutamide on ATP-sensitive K+ channels from human right atrial cardiac myocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Pro-arrhythmic effect of nicorandil in isolated rabbit atria and its suppression by tolbutamide and quinidine

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of nicorandil administration on survival rate and arrhythmias during reperfusion in anesthetized rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of K(ATP) channel blockade by glibenclamide on the warm-up phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Blockade of K(ATP) channels with glibenclamide does not abolish preconditioning during demand ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Attenuation of myocardial ischemia with repeated exercise in subjects with chronic stable angina: relation to myocardial contractility, intensity of exercise and the adenosine triphosphate-sensitive potassium channel

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Blockade of vascular ATP-sensitive potassium channels reduces the vasodilator response to ischaemia in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Effects of tolbutamide on vascular ATP-sensitive potassium channels in humans. Comparison with literature data on glibenclamide and glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Is metformin cardioprotective?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970030-7

7 January 2021

10.1016/S1262-3636(07)70030-7

Identifiers

DOI

1 reference

26 June 2017

1 reference